Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of Regorafenib and XELOX Combination as 2nd Line Treatment in Metastatic Colorectal Cancer Patients

NCT04008511 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.

NCT NCT04008511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04008511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of Regorafenib and XELOX Combination as 2nd Line Treatment in Metastatic Colorectal Cancer Patients
Lead sponsor
China Medical University, China
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2019
Completion date
March 31, 2024
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer